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Abstract
Occurrence of Lewy bodies (LBs)/Lewy neurites (LNs) containing misfolded fibrillar a-synuclein (a-syn) is one of the
pathologic hallmarks of memory impairment-linked synucleinopathies, such as Parkinson’s disease (PD) and demen-
tia with LBs (DLB). While it has been shown that brainstem LBs may contribute to motor symptoms, the neuropatho-
logical substrates for cognitive symptoms are still elusive. Here, recombinant mouse a-syn fibrils were bilaterally
injected in the hippocampus of female Sprague Dawley rats, which underwent behavioral testing for sensorimotor
and spatial learning and memory abilities. No sensorimotor deficits affecting Morris water maze task performance
were observed, nor was any reference memory disturbances detectable in injected animals. By contrast, significant
impairments in working memory performance became evident at 12months postinjection. These deficits were associ-
ated to a time-dependent increase in the levels of phosphorylated a-syn at Ser129 and in the stereologically esti-
mated numbers of proteinase K (PK)-resistant a-syn aggregates within the hippocampus. Interestingly, pathologic
a-syn aggregates were found in the entorhinal cortex and, by 12months postinjection, also in the vertical limb of the
diagonal band and the piriform cortices. No pathologic a-syn deposits were found within the substantia nigra (SN),
the ventral tegmental area (VTA), or the striatum, nor was any loss of dopaminergic, noradrenergic, or cholinergic
neurons detected in a-syn-injected animals, compared with controls. This would suggest that the behavioral impair-
ments seen in the a-syn-injected animals might be determined by the long-term a-syn neuropathology, rather than
by neurodegeneration per se, thus leading to the onset of working memory deficits.
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Significance Statement
Cognitive deficits represent significant non-motor manifestation of Parkinson’s disease (PD) and dementia
with Lewy body (LB), which deteriorates daily living activities leading to reduced independence, quality of
life, and survival of affected patients. Therefore, the identification of anatomic and neuronal substrates
underlying cognitive impairment can help in the development of appropriate treatments. Our data, confirm
and extend previous observations showing that hippocampal a-synuclein (a-syn) pathology contribute to
specific memory impairment. Thus, the a-syn preformed fibril (a-syn PFF) infusion procedure in the rat may
represent a feasible tool to model synucleinopathies with which to test possible therapeutic interventions.
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Introduction
a-Synuclein (a-syn) is an intrinsically disordered 140-
amino acid brain protein, predominantly a-helical struc-
tured when bound to membranes and widely present at
presynaptic terminals in soluble and membrane-associ-
ated forms (Maroteaux et al., 1988). a-Syn may fold into a
b -sheet-rich structure able to polymerize into highly toxic
amyloid fibrils and aggregates (Eliezer et al., 2001;
Uversky, 2007). Although largely unknown, a-syn is
thought to be involved in synaptic vesicle release and traf-
ficking, physiological regulation of enzymes and trans-
porters, and neuronal apoptotic responses (Dev et al.,
2003). a-Syn also constitutes the filamentous neuronal in-
clusions known as Lewy bodies (LBs) and Lewy neurites
(LNs), which characterize a group of neurodegenerative
diseases called synucleinopathies, including Parkinson’s
disease (PD), dementia with LBs (DLB), and multiple sys-
tem atrophy (MSA; Lee et al., 2010; McCann et al., 2014).
The pathophysiological mechanisms underlying synuclei-
nopathies are still poorly understood; however, recent
findings suggest that aggregated forms of a-syn act with
a prion-like mechanism (Luk et al., 2012; Masuda-
Suzukake et al., 2013; Aulic et al., 2014). Over the last
decades, transgenic PD models have been generated ex-
pressing moderate levels of a-syn over long periods, as it
occur in the disease (Polymeropoulos et al., 1997; Singleton
et al., 2003; Antony et al., 2011; Visanji et al., 2016). While
valuable, however, transgenic PD models do not recapitu-
late other pathologic hallmarks of the disease, including ni-
grostriatal degeneration and motor disturbances (Blesa and
Przedborski, 2014). Neurotoxic paradigms, such as intrace-
rebral injection of 6-hydroxydopamine (6-OHDA) in rodents
(Breese and Traylor, 1971) or 1-methyl-4-phenyl-1,2,3,6-tet-
rahydropyridine (MPTP) in non-human primates (Langston
et al., 1984), have been widely used, both leading to a rapid
nigrostriatal degeneration associated to robust motor
deficits (Meredith et al., 2008). However, none of these mod-
els exhibit a-syn and LBs/LNs pathology (Schober, 2004;
Jackson-Lewis et al., 2012). With the introduction of viral
vector-based models of PD (Kirik et al., 2002), all major PD
hallmarks have been obtained in rats and mice (Decressac
et al., 2012; Oliveras-Salvá et al., 2013). However, the supra-
physiological level of a-syn, rapid time course of the pathol-
ogy (one to twomonths), and circumscribed (rather than
widespread) a-syn aggregation seen in these animals have
raised concerns (Braak et al., 2003; Oliveras-Salvá et al.,
2013).
Following the hypothesis of a potential prion-like mecha-
nism for a-syn propagation, a-syn preformed fibrils (a-syn
PFFs) have been used either in vitro or microinjected into
specific rodent brain areas in vivo, triggering a-syn pathol-
ogy, synaptic dysfunction, perturbations in cell excitability,
and cell death in vitro (Luk et al., 2009; Volpicelli-Daley et
al., 2011), as well as a-syn inclusions resembling those
found in patients, also in distally located target regions, in
vivo (Paumier et al., 2015). The a-syn PFFmodel, therefore,
provides a valuable tool to replicate some aspects of histo-
pathology in PD (Patterson et al., 2019).
While brainstem LBs are thought to contribute to motor
symptoms, the neural substrate for cognitive symptoms in
PD remains elusive and a matter of debate. Consistent with
Braak hypothesis, suggesting a caudal to rostral spread of
LB/LN pathology (Braak et al., 2003), several studies have
reported that cortical or limbic LBs/LNs correlate with de-
mentia in PD (Hurtig et al., 2000; Harding and Halliday,
2001; Apaydin et al., 2002; Kövari et al., 2003; Aarsland et
al., 2005; Irwin et al., 2012). Interestingly, a potential hippo-
campal LB involvement in cognitive impairments is further
supported by significant correlations between cognitive per-
formances of DLB patients and postmortem LB pathology
in hippocampal cornu ammonis (CA)1 (Adamowicz et al.,
2017). Surprisingly, however, no study to date has ad-
dressed the anatomic, molecular, and functional effects of
a-syn PFF following injection in the hippocampus, a region
known to be crucial for learning andmemory (Squire, 1992).
Considering the above results and limitations, the pres-
ent study sought to investigate the progressive pathologic
alterations and spreading of synthetic a-syn fibrils bilater-
ally injected into the hippocampus of adult rats, up to the
onset of memory impairments.
Materials and Methods
Expression and purification of recombinant mouse
a-syn
a-Syn was prepared as described previously (Huang et
al., 2005). Briefly, recombinant a-syn protein was purified
from Escherichia coli BL21 (DE3) cells expressing mouse
a-syn construct from the pET11a expression vector. E.
coli cells were grown in minimal medium at 37°C in the
presence of ampicillin (100 g/ml) until OD600 of ;0.6, fol-
lowed by induction with 0.6 mM IPTG for 5 h. The protein
was extracted from periplasm by osmotic shock, followed
by boiling for 20min and ammonium sulfate precipitation.
The protein was next purified by anion exchange chroma-
tography (HiTrap Q FF column, GE Healthcare), and
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fractions were analyzed by SDS-PAGE. Finally, the protein
was dialyzed against water, lyophilized, and stored at80°C.
Fibrillation of mouse a-syn
Before fibrillation, the protein was filtered (0.22-mm sy-
ringe filter), and the concentration was determined by ab-
sorbance measured at 280 nm, then the fibrillation was
performed as described previously (Aulic et al., 2017).
Briefly, purified mouse a-syn (1.5mg/ml) was incubated in
the presence of 100 mM NaCl and 20 mM Tris-HCl, pH 7.4.
Reactions were performed in a black 96-well plate with a
clear bottom (PerkinElmer), in the presence of one 3-mm
glass bead (Sigma) in a final reaction volume of 200 ml.
Plates were sealed and incubated in BMG FLUOstar
Omega plate reader at 37°C with cycles of 50 s of shaking
(400 rpm, double-orbital) and 10 s of rest. After fibrillation,
the reaction mixtures were ultracentrifuged for 1 h at
100,000  g (Optima Max-XP, Beckman), sonicated for
5min (Branson 2510), and resuspended in sterile PBS, ali-
quoted, and stored at 80°C until use. The resulting
a-syn fibril assemblies were then structurally character-
ized by atomic force microscopy (AFM) as previously de-
scribed (Aulic et al., 2017; Extended Data Fig. 1-1).
Animals and experimental design
Thirty-six young adult female Sprague Dawley rats (pro-
vided by the animal facility at the University of Trieste)
weighing 220–250 g at the time of surgery were housed in
high efficiency, particulate air-filtered, double-decker cage
units (Tecniplast), and maintained under standard condi-
tions of temperature, light, and humidity, with ad libitum ac-
cess to food and water. The animals were randomly
assigned to groups receiving bilateral intrahippocampal in-
jections of recombinant mouse a-syn PFF (n=18) or PBS
alone (sham injected, n=10), whereas the remaining animals
(intact, n=8) were not injected and served as unoperated
controls. Subgroups of randomly selected animals (five
a-syn-treated, three sham-injected, and two intact rats)
were killed at approximately seven and nine months post-
surgery, whereas the remaining subjects (8 a-syn-treated,
four sham-injected, and four intact rats) were allowed to sur-
vive up to 12months postinjection. Behavioral analyses
were begun at approximately threemonths postinjection
and consisted in the sequential administration of tests spe-
cifically designed to evaluate sensorimotor as well as spatial
reference and working memory abilities. Upon completion
of the last testing session, at each of the predetermined
time points, the animals were killed, and the brains proc-
essed for quantitative immunohistochemistry or Western
blot analyses. All the experimental procedures were con-
ducted following the Italian Guidelines for Animal Care (D.L.
116/92 and 26/2014), which are in compliance with the
European Communities Council Directives (2010/63/EU)
and were approved by the Ethical Committee at the
University of Trieste.
Surgical procedures
Stereotaxic injections of recombinant, freshly sonicated
mouse a-syn PFF bilaterally into the hippocampus were
performed on rats under deep anesthesia (sodium pento-
barbital, 40mg/kg, i.p.). Briefly, 7.5 mg of the protein was
injected using a 10-ml Hamilton microsyringe (Hamilton),
in a volume of 5-ml sterile PBS per side at the following
stereotaxic coordinates according to Paxinos and
Watson (1998): AP = –3.6; ML = 61.8; DV = –3.6 (in mm,
relative to bregma and outer skull surface). The dose and
volume were chosen based on the results of pilot experi-
ments. Each infusion was conducted over 5min, waiting
for additional 2min before withdrawal, to prevent back-
flow and reduce tissue damage. For sham treatment, ster-
ile PBS was injected using the same coordinates, volume,
and speed.
Behavioral tests
Starting from approximately threemonths postinjection,
the animals underwent a battery of behavioral tests (nor-
mally administered between 9 A.M. and 3 P.M.) con-
ducted at different time points, to evaluate possible
effects of the treatments on sensorimotor and cognitive
functions and their time course (Fig. 1). All the behavioral
paradigms were based on modified versions of the water
maze task originally developed by Morris (1984) for the
assessment of spatial learning and memory in rodents.
The test apparatus consisted of a circular pool, 140 cm in
diameter and 50 cm deep, filled with room temperature
water to a depth of 35 cm and located in a room with sev-
eral external cues that could be used for orientation. Four
equally spaced points (conventionally indicated as North,
South, East, and West) served as start locations, also di-
viding the tank into four quadrants. A circular platform
(10 cm in diameter) was fixed to the bottom of the pool
with it top 2 cm below (and thus invisible from) the water
surface. In the middle of each quadrant, a circular area of
;20 cm in diameter (termed annulus) indicated the site
where the escape platform could have been, if placed in
that quadrant. For each animal, the latency to find the hid-
den platform, the distance swum, and the swim speed
were recorded by a computer-based video-tracking
system.
Three different paradigms, designed to evaluate the
sensorimotor, as well as reference and working memory
abilities (Coradazzi et al., 2016; Pintus et al., 2018), were
implemented.
Cued test
All animals first received a free 60-s swim to become fa-
miliar with the swimming pool, followed by a 3-d cued
learning session to exclude the occurrence of noncogni-
tive (e.g., visual) deficits, induced by the treatment, that
may interfere with the correct execution of the test. During
the cued task, the position of the escape platform was
made visible by a 10 15-cm striped flag and randomly
changed on each of four daily trials.
Morris water maze test
Three days after conclusion of the cued test, the ani-
mals were subjected to the Morris water maze test for the
assessment of reference memory. The animals were
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given four trials per day over five consecutive days with a
30-s intertrial time. On each trial, the animal was released
into the pool from one of the starting points and then
given 60 s to locate the platform [constantly kept in the
North-East (NE) quadrant] and climb onto it. If the sub-
merged platform was not found, the rat was gently guided
by the experimenter and left on it for ;30 s, before be
placed in the next predetermined starting point, whose
sequence was defined randomly, and it was changed
every day. On the fifth day of testing, after the fourth trial,
the platform was removed and a spatial probe trial com-
menced, during which the animals were allowed to swim
freely for 60 s. In this test, generally used to evaluate the
efficiency of the previous learning, the distance swum as
well as the collisions with the annuli in each of the four
quadrants, were recorded. In order to check for possible
delayed long-term effects of the a-syn treatment on refer-
ence memory, a separate 3-d Morris water maze test,
with a spatial probe trial, was administered to the animals
just before killing, at;12months postinjection.
Radial armwater maze (RAWM) test
Spatial working memory was tested using a RAWM ap-
paratus consisting in six swim alleys (50 cm long  20 cm
wide, numbered 1–6) radiating out of an open central area
in the same pool. The submerged escape platform was
placed at the end of an arm (referred to as the goal arm),
and its position was changed every day over five consec-
utive days. In each of the five daily trials, the animals were
released from a different starting position and given up to
60 s to locate the hidden platform with a 30-s intertrial
time. Entering an incorrect arm (i.e., an arm that did not
contain the platform or an already visited arm) was
counted as an entry error. For each trial, the latency to
find the platform and the number of arm selection errors
before locating the goal arm were recorded. The task de-
sign entails that the animals locate the platform by chance
on the first trial each day (and thus no group difference is
expected), whereas in the second and subsequent trials,
the acquired information on the novel platform location
for that day would determine substantial improvements in
performance. Therefore, differences in latency or error
scores between trials 1 and 2 across days, both in abso-
lute terms and as percentage of trial 1 (savings) provided
measures of working memory performance.
Two-trial RAWM test
In the original five-trials-a-day paradigm, the RAWM
testing is conducted over five consecutive days, allowing
animals to get used to the task contingencies and to ex-
clude all the unspecific factors that may affect perform-
ance. In this case, cutting the general duration of the test
from 5 to 2 d modified the RAWM standard paradigm, as
the animals were already well habituated to the environ-
ment and have learned the rules of the task. In addition,
the number of trials administered every day was reduced
from five to two as it was noticed previously that the main
improvement in the RAWM performance mainly occurs
between the first and second trial. Thus, from fivemonths
postinjection and onwards, two two-trial RAWM tests
were administered over two consecutive days each week,
organized as two adjacent blocks of six weekly sessions
each. Starting from approximately the ninth month postin-
jection, the animals received the same two two-trial
RAWM testing sessions, but every second week, until sig-
nificant group differences in the savings for both latency
and errors were detected over three consecutive testing
sessions. Subsequently, the delayed 3-d Morris water
maze test was administered, as mentioned above (see
also Fig. 1).
Postmortem procedures
Upon conclusion of behavioral tests, at approximately
seven and nine months postinjection, the animals under
terminal anesthesia (chloral hydrate, 350mg/kg, i.p.) were
perfused through the ascending aorta with room tempera-
ture saline, followed by ice-cold phosphate-buffered 4%
paraformaldehyde (pH 7.4). The brains were rapidly re-
moved, kept in the same fixative for 2 h and then trans-
ferred in a phosphate-buffered 20% sucrose solution at
4°C until they had sunk. Coronal sections at 40-mm thick-
ness were cut using a freezing microtome (Leitz Wetzlar)
from the prefrontal cortex level through the basal fore-
brain to the level of the caudal hippocampus and col-
lected into six series. The sections were then stored
at –20°C in a phosphate-buffered antifreeze solution con-
taining 30% glycerol and 30% ethylene glycol, pending
immunohistochemical analysis.
Animals allowed to survive up to 12months postinjec-
tion, under terminal anesthesia as above, were perfused
Figure 1. Experimental time-line diagram illustrating the temporal sequence of surgery, behavioral tests, killings, and the intervals
between them. See also Extended Data Figure 1-1.
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through the ascending aorta with room temperature sa-
line. After rapid removal, and using a counterbalanced
left–right dissection schedule, the whole hippocampus,
the prefrontal, fronto-parietal, and entorhinal cortices from
one hemisphere were dissected free onto a chilled glass
plate, immediately frozen in crushed dry-ice, and kept at –
80°C for Western blot assay (see section Western blotting).
The remaining portions of the brain, which comprised the
cortical and hippocampal regions from the opposite hemi-
sphere, both striata and the entire basal forebrain were
fixed by 24-h immersion in ice-cold phosphate-buffered
4% paraformaldehyde (pH 7.4), soaked in phosphate-buf-
fered 20% sucrose and then cut as above.
Immunohistochemistry
For the detection of proteinase K (PK) resistant a-syn ag-
gregates, one series of free-floating coronal sections were
first quenched in 3% H2O2 and 10% methanol for 10min to
eliminate endogenous peroxidase activity, and then treated
30min with 5mg/ml of PK. After blocking unspecific binding
sites with 5% normal goat serum (NGS; Immunologic
Sciences), and 0.3% Triton X-100 in PBS (KPBS, pH 7.4) for
2 h, the sections were incubated overnight with a rabbit anti-
a-syn primary antibody (C20-R, Santa Cruz Biotechnology,
1:500), 2% NGS, and 0.3% Triton X-100 in KPBS.
Subsequently the sections were incubated with a biotinylated
secondary antibody (goat anti-rabbit 1:300, Vector), 2%
NGS, and 0.3% Triton X-100 in KPBS for 1 h. After this step,
the sections were incubated with avidin biotin peroxidase
complex (Vectastain ABC alite kit, Vector) for 1 h and then re-
acted with 0.025% diaminobenzidine and 0.01% H2O2 in
KPBS for 3–5min. The sections were mounted on gelatin-
coated slides, dehydrated through steps in ascending alcohol
concentrations, clarified in xylene, and coverslipped for sub-
sequent microscopical analyses. In order to ensure consis-
tency during morphometric analyses (see below), tissue
processing and staining were conducted under identical con-
ditions, using all relevant sections at a time. Control tissue
specimens, not exposed to the primary antibody, were also
used to check for nonspecific labeling. All steps were per-
formed at room temperature.
Cresyl violet staining was performed as previously de-
scribed (Gulino et al., 2019). Briefly, sections were dehy-
drated with increasing ethanol and then soaked in xylene.
Dehydrated sections were then rehydrated and stained
with a solution of 0.2% sodium acetate, 1% cresyl violet,
and 3% glacial acetic acid in water for 10min at room
temperature. Sections were then washed in water, dehy-
drated through steps in ascending alcohol concentra-
tions, clarified in xylene, and coverslipped.
For double immunofluorescence, free-floating sections
were incubated overnight at room temperature with a rab-
bit anti-phospho-a-syn(Ser129; D1R1R) primary antibody
(Cell Signaling, 1:1000) and a monoclonal mouse anti-
GFAP antibody (Sigma, 1:400). The sections were then in-
cubated with an Alexa Fluor 488-conjugated goat anti-
rabbit secondary antibody (Life Technologies, 1:200) and
then with an Alexa Fluor 594-conjugated goat anti-mouse
(Life Technologies, 1:200) for 2 h in the dark. The 49,6-dia-
midino-2-phenylindole (DAPI; Sigma 1:200) compound
was used for nuclear staining. Slides were mounted with
Fluoromount Aqueous Mounting Medium (Sigma) and im-
ages were acquired using a Leica confocal microscope
(Leica TCS SP2).
Western blotting
The cortices and the hippocampi dissected for the mea-
surement of non-phosphorylated, Ser129-phosphorylated
a-syn and cellular prion protein (PrPC) expression levels
were homogenized using a manual dounce homogenizer in
a radioimmunoprecipitation assay (RIPA) buffer containing
150 mM NaCl, 0.1% Triton X-100, 0.5% sodium deoxycho-
late, 0.1% sodium dodecyl sulfate (SDS), 50 mM Tris-HCl
(pH 8.0), 1 phosSTOP (Roche Diagnostic), and 1 prote-
ase inhibitor cocktail (Roche Diagnostic). The homogenates
were centrifuged at 10,000 rpm for 10min at 4°C and the
supernatants collected and stored in aliquots at80°C until
use. Total protein content of brain homogenates was meas-
ured using bicinchoninic acid protein (BCA) quantification
kit (Pierce) and 25mg/ml of brain homogenates were resus-
pended in Laemmli loading buffer, boiled for 5min at 100°C
for denaturation. Subsequently the samples were loaded
onto the Mini-PROTEAN TGX Precast Gels (Bio-Rad), trans-
ferred to PVDFmembranes (Immobilon-P, Millipore), and in-
cubated for 30min with 4% paraformaldehyde (PFA) in PBS
to better detect endogenous Ser129-phosphoryated a-syn
(Sasaki et al., 2015). By contrast, no PFA treatment was em-
ployed for the detection of non-phosphorylated a-syn and
PrPC. After incubation, the membrane was washed in TBS-
T (0.1% Tween 20 in TBS) for 10min, treated with 5% non-
fat milk or bovine serum albumin (BSA; w/v, in PBS) block-
ing solution for 1 h at room temperature in agitation and
then incubated overnight at 4°C with the following primary
antibodies: rabbit polyclonal anti-phospho-S129 a-syn
(Abcam, ab59264 1:1000), rabbit polyclonal anti-a-syn (C-
20-R, Santa Cruz Biotechnology, 1:1000), mouse monoclo-
nal anti-PrPC (clone P, kindly provided by Prof. S. Prusiner,
1:1000), and a mouse monoclonal anti b -actin (1:50,000,
A3854 Sigma-Aldrich), all diluted in blocking solution.
Membranes were washed with TBST and incubated in
horseradish peroxidase (HRP)-conjugated goat anti-rab-
bit (DAKO, 1:1000) or goat anti-mouse (DAKO 1:1000)
secondary Ab for 1 h. The membranes were washed in
TBST, and proteins were visualized following the manu-
facturers’ instructions using GE Healthcare ECL Western
Blotting Detection reagent (GE Healthcare) with UVITEC
Cambridge. Quantitative densitometry analysis of pro-
teins was performed using UVBand software (UVITEC
Cambridge).
Stereology
All analyses were conducted on coded slides by investi-
gators blinded to the groups’ identity. The occurrence of
PK-resistant a-syn-immunoreactive deposits, as either
LB-like inclusions (defined as dense, darkly stained intra-
neuronal cores) or LN-like inclusions (defined as dense,
darkly stained neurites) in the hippocampal formation,
was quantified using an unbiased stereological estimation
method based on the optical fractionator principle (West
Research Article: New Research 5 of 20
May/June 2020, 7(3) ENEURO.0009-20.2020 eNeuro.org
et al., 1991). a-Syn-immunoreactive neurons and proc-
esses were counted bilaterally in the CA1 subfield of the
hippocampus and in the dentate gyrus (DG; i.e., the areas
in close proximity to the injection site), using;10 sections
per rat located between 2.1 and 4.5 mm caudal to breg-
ma. The same analyses were also conducted to quantita-
tively estimate the presence of a-syn-immunoreactive
deposits in projection areas outside the injection site,
namely the entorhinal cortex. The sampling system con-
sisted of an Olympus BH2 microscope (fitted with an X-Y
motorized stage and a microcator to measure distances
in the z-axis) interfaced with a color video camera (Sony)
and a personal computer. The CAST GRID software
(Olympus Denmark A/S) was used to delineate the hippo-
campus area at 4 magnification, as well as to generate
unbiased counting frames which were moved randomly
and systematically until the entire delineated area was
sampled. Using a 100 oil objective, unambiguously pos-
itive aggregates were identified and counted. For each
animal, estimates of the total numbers of neuronal and
neuritic aggregates in the hippocampus and entorhinal
cortex were obtained according to the optical fractionator
formula and then plotted as mean 6 SEM for each time
point analyzed. Accuracy of the stereological procedure
was evaluated following (Gundersen and Jensen, 1987),
and values,0.1 were considered acceptable.
RNA extraction and quantitative real-time PCR (qRT-
PCR) analysis
Total RNA was isolated from;300mg of prefrontal cor-
tex and hippocampus from frozen postmortem rat brain
tissue. RNA processing and qRT-PCR experiment were
the same as reported previously (Vanni et al., 2017) and
the primers sequences were as follows: for Actb forward
CTGTGTGGATTGGTGGCTCT reverse CAGCTCAGTAA
CAGTCCGCC; for Snca forward TGTCAAGAAGGACC
AGATGGG reverse TAGTCTTGGTAGCCTTCCTCT and
for Prnp forward CGGTACCAGTCCGGTTTAGG reverse
GCTTTTTGCAGAGGCCAACA. Differential gene expres-
sion of Scna and Prnp was normalized to Actb expression.
The relative expression ratio was calculated using the DDCT
method (Livak and Schmittgen, 2001).
Statistical analysis
Data fulfilled the criteria for normal distribution and were
therefore analyzed using parametric tests for all statistical
comparisons. Group differences in behavioral performance
as well as in the numbers of immunostained profiles or
a-syn expression levels were evaluated by either repeated
or one-way ANOVA, as appropriate, followed by Fisher’s
protected least significant difference (PLSD) post hoc test.
All data are presented as mean 6 SEM, and differences
were considered significant at p, 0.05.
Results
Behavioral analyses
All animals, regardless of their treatment, increased in
body weight and exhibited fairly normal sensorimotor func-
tioning when evaluated in the 3-d cued test at threemonths
postinjection (Fig. 2). In fact, the groups improved their per-
formance over time (repeated measures ANOVA, effect of
day on latency, F(2,66) = 51.79; on distance, F(2,66) = 42.44;
both p,0.001) and did not differ from each other (main
group effect on latency F(2,33) = 0.11; on distance F(2,33) =
0.13; group  day on latency F(4,66) = 0.23; on distance
F(4,66) = 0.23; all not significant (n.s.)). Moreover, swim speed,
monitored as a measure of motor ability throughout the exe-
cution of the various tasks, averaged 0.2–0.3 m/s, and did not
differ between groups at any time point, indicating that the
treatments did not produce any sensory ormotor impairments
that would affect navigation search in the pool. As revealed by
statistics, rats with sham injections did not differ from the in-
tact animals on any of the behavioral or morphologic parame-
ters analyzed. These animals were therefore combined into a
single control group (n=18) for all illustrations.
Morris water maze test
Mean latencies and swim distances required to find the
hidden platform in the reference memory version of the
Figure 2. Groups performance during the cued version of the Morris water maze test at threemonths postinjection. In this task, the
visually cued escape platform was moved to a different quadrant on each of the four daily trials, and average escape latencies (A)
and swim distances (B) were recorded. Each point represents the mean value 6 SEM for the block of four trials administered each
day, over the three training days.
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Morris water maze task administered at threemonths
postinjection are shown in Figure 3A,B. All animals rapidly
learned to locate the platform and improved significantly
over the five testing days (repeated measures ANOVA,
effect of day on latency, F(4,132) = 43.93; on distance,
F(4,132) = 40.58; both p,0.001), reaching an asymptotic
performance already on day three. The animals appeared
to learn the tasks at similar rates, and no significant differ-
ences were observed between the groups (main group ef-
fect on latency F(2,33) = 0.47; on distance F(2,33) = 0.60;
group per day on latency, F(8,132) = 0.16; on distance
F(8,132) = 0.18; all n.s.). During the spatial probe trial, on
the last day of testing, when the platform was removed for
a 60-s free swim (Fig. 3C–E), all animals swam primarily in
the training (NE) quadrant, where the platform was origi-
nally located (repeated measures ANOVA, effect of quad-
rant on swim distance, F(3,99) = 36.73; on annulus
crossings, F(3,99) = 74.06, both p, 0.001), with equal effi-
ciency (main group effect on distance F(2,33) = 0.67; on an-
nulus crossings, F(2,33) = 1.87; group per quadrant
Figure 3. Performance during the Water maze reference memory test at threemonths postinjection. Average latency (A) and swim
distance (B) required to locate the submerged platform during the acquisition phase of the spatial navigation task. Each sample
point represents the mean value 6 SEM for the block of four trials on each of the five consecutive days of testing. Lower diagrams
illustrate the mean relative distance swum (C) and the average number of annulus crossings (D) in each quadrant during the spatial
probe trial, once the escape platform was removed from the NE (training) quadrant. In E, the actual swim paths taken by representa-
tive animals from the different groups are shown. All groups exhibited an equally efficient performance, indicating that the a-syn in-
jection had no effects on this task. NE, North-East; NW, North-West; SE, South-East; SW, South-West.
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interaction for distance, F(6,99) = 1.35; for annulus crossings
F(6,99) = 1.39; all n.s.). In addition, no group difference was ob-
served in the total number of collisions with the annuli or swim
speed (one-way ANOVA, main group effect, respectively,
F(2,33) = 1.87 and F(2,33) = 0.01; both n.s.), indicating an equally
active and spatially focused search behavior in all animals.
At ;12months postsurgery, on conclusion of the last
two-trial RAWM session (see below), the animals were
tested again in the Morris water maze task to evaluate
possible delayed effects of the injected a-syn PFF, as a
result of their progressive spreading. Only the data refer-
ring to the spatial probe trial will be reported here (Fig.
4A–C). Consistent with the observations at the three-
month time point, the a-syn treatment produced no
long-term impairments in reference memory abilities. In
fact, all tested animals exhibited an equally efficient and
focused search behavior in the spatial probe trial (re-
peated measures ANOVA effect of quadrant on swim
distance, F(3.39) = 9.31; on annulus crossings F(3.39) =
19.49; both p, 0.001), with no obvious group differen-
ces (main group effect on distance, F(2,13) = 1.29; on an-
nulus crossings, F(2,13) = 2.00; group  quadrant
interaction for distance, F(6,39) = 1.25; for annulus cross-
ings F(6,39) = 1.76; all n.s.). This applied also to the total
number of crossings or swim speed.
RAWM test
Group performances in the RAWM task, when first ad-
ministered at threemonths postinjection, are shown in
Figure 5A–E. In this design, the platform position was
moved to a new arm daily, thus the animals had to re-
learn its position within the five trials of each testing day
by developing a new search strategy. As expected, all ani-
mals required a longer latency and made a higher number
of arm selection errors (i.e., entering an arm not containing
the platform or an arm which had already been visited)
during the first trial of each day, but they improved over
the five trials (repeated measures ANOVA, effect of trial on
latency, F(4,132) = 57.76; on errors, F(4,132) = 45.69; both
p, 0.001). At the three-month time point, the ability to
progressively reduce the latency and errors required to lo-
cate the hidden platform was similar for all animals, and
no group difference was detected (main group effect on la-
tency, F(2,33) = 0.19; on errors F(2,33) = 0.45; group per trial in-
teraction on latency F(8,132) = 0.67; on errors, F(8,132) = 0.55;
all n.s.). Inspection of latency and errors savings, calculated
as percentage improvement between trials 1 and 2, con-
firmed a ; 40–48% reduction of latency and entry errors,
with no obvious group difference (one-way ANOVA with
Fisher’s PLSD post hoc test; all n.s.). The swim paths ob-
tained on the fifth day of training from representative animals
are shown in Figure 5E.
Two-trials RAWM test
Starting from fivemonths and up to;12months postin-
jection, the animals were tested using a modified version
of the RAWM task, with two daily trials administered over
two consecutive days. The testing was then organized,
with intervening killings of randomly selected subjects
from the various groups at different time points postinjec-
tion, so as to have three main blocks of six sessions ad-
ministered weekly or every two weeks, as outlined above.
By such design, latency and error savings, calculated as
percentage improvement from trial 1 to 2, provided a
measure of working memory performance and its possi-
ble changes over time (Fig. 6A–C). During the first two
blocks (weekly sessions 1–6 and 7–12 starting at five and
sevenmonths postinjection, respectively) animals in the
Figure 4. Performance during the spatial probe trial of the separate 3-d Morris water maze test administered just before killing, at
12months postinjection. The mean relative distance swum (A), the average number of annulus crossings (B), and the actual swim
paths taken by representative animals from the different groups (C) are illustrated. Consistent with the observations at the three-
month time point, no long-term impairments in reference memory abilities were produced by the a-syn treatment.
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groups were equally efficient in reducing both escape la-
tency and number of errors across trials, and no signifi-
cant group difference was detected (one-way ANOVA, all
p. 0.05, n.s.). By contrast, in the third block of sessions
(administered every two weeks starting from the ninth
month postinjection), a-syn-treated animals were seen to
progressively worsen their performance. In fact, the cal-
culated percent improvements in both latency and errors
appeared significantly lower than those exhibited by the
sham-injected and intact groups already on session 15
(one-way ANOVA, p, 0.01 or p, 0.05 for both measures),
and remained unmodified up to session 18, when the
training criterion (i.e., significant group differences in at
least three consecutive sessions) was considered ful-
filled and the two-trial RAWM testing was interrupted
(actual swim paths from representative animals are il-
lustrated in Fig. 6C).
Morphologic analyses
Consistent with previous observations (Aulic et al.,
2017), sonication of a-syn fibrils resulted in the formation
Figure 5. Working memory performance in the RAWM task, at threemonths postinjection, illustrating latency (A) and number of entry errors
(B) required by the animals to find the hidden platform. Each sample point represents the mean latency and errors 6 SEM recorded during
each 60-s trial over five consecutive testing days. In the lower diagrams, performances are plotted as percent savings between trials 1 and
2 for latency (C) and errors (D). In E, the actual swim paths taken by representative animals from the different groups are illustrated. All
groups exhibited an equally efficient performance, indicating no clear-cut effects of a-syn on working memory at this time point.
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Figure 6. Working memory performance during the two trials RAWM, from five to 12months postinjection. Data represent the
percentage rate of improvement between the first and the second trial (savings) in latency (A) and errors (B). All groups ex-
hibited an equally efficient working memory during the first two blocks of weekly sessions, administered at five and
sevenmonths postinjection, respectively; however, a-syn-treated animals progressively worsened their performance and ap-
peared significantly impaired during the third block of sessions, administered every two weeks. In C, the actual swim paths
taken by representative animals from the different groups in the various blocks are illustrated. Asterisks indicate significant
difference from control at p, 0.01.
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of relatively small and homogeneous fibrillary assemblies,
as revealed by AFM (Extended Data Fig. 1-1). By contrast,
no such pattern was exhibited by the non-preaggregated
protein (data not shown).
The bilateral injection of synthetic mouse a-syn fibrils
into the hippocampus resulted in the occurrence and pro-
gressive accumulation of a-syn-immunoreactive aggre-
gates in various hippocampal subfields (e.g., DG and
CA1; Fig. 7G–L’), whereas no such a-syn aggregates
were found in the brain of sham-injected or intact animals
(compare, e.g., with corresponding regions in control ani-
mals; Fig. 7A–F’). In general, the strong PK-resistant
a-syn immunoreactivity occurred as both LB-like and LN-
like deposits (Fig. 7M,N) and was detected not only in the
proximity of the injection site but also in distinct anatomi-
cally related regions, with a morphology and distribution
pattern that varied in a time-dependent fashion. Thus, as
estimated by stereology, relatively few a-syn-immunore-
active LB-like inclusions were found in the hippocampal
CA1 and DG subfields at approximately sevenmonths
Figure 7. Representative micrographs illustrating, on the coronal plane, the negligible expression of PK-resistant a-syn immunore-
activity at seven, nine, and 12 months postinjection in the hippocampal DG (A–C, insets shown in A’–C’) and in the CA1 region
(D–F, insets shown in D’–F’) of control rats. Progressive aggregation of a-syn after injection of recombinant mouse a-syn fibrils into
the hippocampus. Compared with control, a strong PK-resistant a-syn immunoreactivity was found at seven, nine, and 12 months
postinjection in the DG (G–I, insets shown in G’–I’) and in the CA1 region (J–L, insets shown in J’–L’) of injected rats. PK-resistant
a-syn aggregates occurred as darkly stained LB-like (arrows) and LN-like deposits (arrowheads) and are shown at higher magnifica-
tion in M, N. Box-whiskers plots illustrate the stereologically estimated numbers at different time points 6 min to max value of
LB-like (O) and LN-like (P) inclusions in the hippocampus of rats injected with the a-syn fibrils. Scale bars: 500 mm (in A, D, G, J for
A–C, D–F, G–I, J–L), 100 mm (in A’, D’, G’, J’ for A’–C’, D’–F’, G’–I’, J’–L’), and 5 mm (M, N). Asterisk in O indicates significant time-
dependent changes at p, 0.05.
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Figure 8. Representative micrographs illustrating, on the coronal plane, the negligible expression of PK-resistant a-syn immunore-
activity at seven, nine, and 12 months postinjection in the entorhinal cortex (A–C, insets shown in A’–C’) of control rats. Progressive
a-syn aggregation after injection of recombinant mouse a-syn fibrils into the hippocampus. A strong PK-resistant a-syn immunore-
activity occurring as both LB-like (arrows) and LN-like (arrowheads) deposits was also found at seven, nine, and 12months postin-
jection in the entorhinal cortex (D–F, insets shown in D9–F9) of injected rats. Box-whiskers plots illustrate the stereologically
estimated numbers at different time points 6 min to max value of LB-like (G) and LN-like (H) inclusions in the two entorhinal cortex
of the injected rats. Scale bar: 500 mm (in A, D for A–C, D–F) and 100 mm (in A’, D’ for A’–C’, D’–F’). Asterisks in G, H indicate signif-
icant time-dependent changes at p, 0.05.
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postinjection, their numbers showing a significant 2.2-fold
and 5.8-fold increase at nine and 12months, respectively
(one-way ANOVA with Fisher’s PLSD post hoc test,
p, 0.05; Fig. 7O). Conversely, the number of LN-like de-
posits in the same regions was slightly higher at
sevenmonths postinjection and exhibited a non-significant
reduction at nine and 12months (Fig. 7P). LB-like and LN-
like inclusions in the entorhinal cortex were virtually unde-
tectable or very sparse at sevenmonths postinjection, but
they became clearly visible already at ninemonths (Fig. 8D–
F’; compare with corresponding regions in control animals,
Fig. 8A–C’), and their numbers increased significantly over
time (one-way ANOVA with Fisher’s PLSD post hoc test,
both p, 0.05; Fig. 8G,H). By contrast, only at 12months
were a-syn-immunoreactive LB-like and LN-like inclusions
found in other projection areas, such as the vertical limb of
the diagonal band, and the anterior and posterior piriform
cortices, being barely detectable at earlier time points (Fig.
9D–F’; compare with corresponding regions in control ani-
mals, Fig. 9A–C’). In either form, occurrence of a-syn immu-
noreactivity in these areas did not appear to result in
disrupted morphology or architecture of local neuronal pop-
ulations. Of note, cresyl violet staining of entorhinal cortex,
hippocampus, and piriform cortex revealed no evidences of
neurodegeneration and/or neuronal loss in a-syn-injected
rats (Fig. 9J–L; compare with corresponding regions in con-
trol animals, Fig. 9G–I). Moreover, separate morphometric
analyses, conducted to assess the possible toxic effects of
a-syn overexpression, revealed that at no time point postin-
jection was any obvious loss of dopaminergic, cholinergic,
or noradrenergic neurons detected in the substantia nigra
(SN), the ventral tegmental area (VTA), medial septum/diag-
onal band of Broca (MS/DBB), or locus coeruleus (LC), re-
spectively. Thus, occurrence and distribution of tyrosine
hydroxylase (TH)-immunoreactive, choline acetyltransfer-
ase (ChAT)-immunoreactive, or dopamine-b -hydroxylase
(DBH)-immunoreactive neurons did not differ between a-syn-
injected and control animals in any of the analyzed regions
(data not shown).
Consistent with the above observations of a time-depend-
ent increase of PK-resistant a-syn aggregates within the
hippocampus, immunofluorescence confirmed the progres-
sive increase of Ser129-phosphorylated a-syn in the hippo-
campus of injected rats (Fig. 10A–C), whereas no such
immunoreactivity was detected in controls (data not shown).
Subsequent analyses of fluorescence intensity and localiza-
tion profile in P-a-syn-GFAP double immunostained speci-
mens at seven, nine, and 12months postinjection revealed
virtually no co-localization of these markers. In fact, close in-
spection of the expression profile plots of P-a-syn and
GFAP immunoreactivities showed very poor or no juxtaposi-
tion between the respective peaks, thus ruling out a glial oc-
currence of Ser129-phosphorylated a-syn as a result of
intracerebral a-syn fibril treatment at any time point postin-
jection (Fig. 10A’–C’, A”–C”).
Long-term effects of a-syn fibril injection
Western blot analyses
At 12months postinjection, Western blot analyses were
conducted on tissue homogenates from the hippocampus
and the prefrontal and frontoparietal cortices of control
and a-syn-injected rats. Because of technical reasons
(accidental loss of the homogenate samples), Western
blot analyses on the entorhinal cortex could not be con-
ducted and will not be reported here. The analyses
were designed to obtain estimates of the relative levels
of non-phosphorylated and Ser129-phosphorylated
a-syn. The procedure (as described above) enabled
the detection of a ;15-kDa band, which represents the
non-phosphorylated a-syn (Fujiwara et al., 2002), a ;80-
kDa which correspond to Ser129-phosphorylated a-syn
(Fig. 11A–C), and a ;35-kDa for PrPC (Fig. 11D–F).
Densitometric analysis of the bands after normalization
against b -actin revealed a significant 50% increase of the
Ser129-phosphorylated a-syn level only in the hippocam-
pus of a-syn-treated rats compared with controls (p,0.01;
Fig. 11A’). By contrast, no group differences in Ser129-
phosphorylated a-syn expression were detected in prefron-
tal and frontoparietal cortices (Fig. 11B’–C’), nor did the
a-syn treatment affect the expression of non-phosphoryl-
ated a-syn in any of the analyzed regions. Likewise, the ex-
pression levels of PrPC in these regions were similar in the
two groups (Fig. 11D’–F’).
qRT-PCR analysis
To evaluate the differential gene expression of Scna
and Prnp, qRT-PCR analysis was performed on tissue
homogenates from prefrontal cortex and hippocampus
of control and a-syn-injected rats at 12months postin-
jection. Consistently, no significant changes in the ex-
pression level of Scna (encoding for a-syn) and Prnp
(encoding for PrPC) mRNA were detected in either the
prefrontal cortex (Fig. 12A) or the hippocampus (Fig.
12B) of a-syn-injected rats as compared with control.
Discussion
The aim of this study was to evaluate the anatomic,
neurochemical, molecular, and behavioral effects of re-
combinant mouse a-syn PFF following intrahippocampal
injection in the adult rat. The injections resulted in the
time-dependent occurrence of PK-resistant a-syn aggre-
gates within the hippocampus, suggesting that neurons in
this region may be particularly susceptible to transmitted
a-syn pathology. Moreover, in keeping with previous find-
ings following intrastriatal/intracortical administration in
mice (Luk et al., 2012), the present data lend support to
the notion that pathologic a-syn can spread over consid-
erable distances to several central regions. In fact, PK-re-
sistant a-syn aggregates were also found in anatomically
related areas, such as the EC, the vDBB, and the piriform
cortices, which, interestingly, was associated to the onset
of specific deficits in spatial working memory, i.e., the
memory function that is commonly impaired in PD pa-
tients (Bradley et al., 1989).
Thus, at sevenmonths postinjection, a-syn immunore-
activity in the hippocampus was mainly associated to
neuritic processes, and relatively few intracellular inclu-
sions were detected. In the hippocampus, the numbers of
Lewy-like neuritic inclusions did not vary significantly over
time, whereas in the EC, the estimated numbers of a-syn-
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Figure 9. Representative micrographs illustrating, on the coronal plane, the negligible expression of PK-resistant a-syn immunore-
activity at seven, nine, and 12 months postinjection in the vertical limb of the DBB (vDBB; A, inset shown in A9), and the anterior
and posterior piriform cortices (aPC and pPC; B, C, respectively, insets shown in B9, C9). Spreading of a-syn aggregates. A strong
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immunoreactive neurites were seen to increase between
seven and ninemonths but remained virtually unchanged
thereafter. In both regions, the immunoreactive material
appeared to progressively invade somata, and already at
ninemonths, the number of neuronal profiles with dense
perinuclear LB-like inclusions was seen significantly
continued
PK-resistant a-syn immunoreactivity was also found at 12months postinjection in the vDBB (D, inset shown in D9, arrow) and the
anterior and posterior piriform cortices (aPC and pPC, E, F, insets shown in E9, F9; arrows and arrowheads indicate LB-like and LN-
like inclusions, respectively). Scale bar: 100 mm (in A, D, for A–C, D–F) and 50 mm (D for D–F). Cresyl violet staining of the entorhinal
cortex (ENT CTX), hippocampus (HPC), and piriform cortices (PC) of control (G, H, I, respectively) and a-syn-injected animals (J, K,
L, respectively). Scale bar: 100 mm (in G for G–L).
Figure 10. Confocal microscopy images illustrating the progressive increase of hippocampal Ser129-phosphorylated a-syn (A–C)
and the lack of co-localization with GFAP at seven, nine, and 12months after the injection of recombinant mouse a-syn fibrils into
the hippocampus. In the lower diagrams, analysis of fluorescence intensity (A’–C’) and surface plot profiles (A”–C”) of confocal im-
ages in A–C indicate very poor or no glial occurrence of the Ser129-phosphorylated a-syn. Scale bars: 50mm (A–C).
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increased. Interestingly, inclusions of a-syn-immunoreac-
tive material in both the hippocampus and EC exhibited
the most dramatic increases (by ;6-fold and 10-fold, re-
spectively) at 12months postinjection. The time course
and dynamics of intracellular a-syn occurrence, with
more dramatic increases detected between nine and 12
months postinjection, i.e., concurrently to the onset of
cognitive impairments, points to a precise time window,
Figure 11. Long-term effects of intrahippocampal a-syn fibril injection on regional tissue levels of Ser129-phosphorylated a-syn (P-
a-syn), non-phosphorylated a-syn (non-P-a-syn), and PrPc. Representative Western blotting bands and densitometric analyses il-
lustrate the expression levels of the various proteins in the hippocampus (A, A’, D, D’), fronto-parietal cortex (B, B’, E, E’), and pre-
frontal cortex (C, C’, F, F’) of rats injected with a-syn fibrils and controls at 12months postinjection. The values are shown as a
percentage of P-a-syn, non-P-a-syn forms, or PrPc relative to b -actin, this latter being the loading control. Data are represented as
mean 6 SEM. Asterisk in A’ indicates significant difference from control at p, 0.05.
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relatively long after its injection into the brain parenchyma,
when a-syn is capable to massively accumulate inside
neurons and efficiently interfere with their function. The
present findings appear consistent with previous obser-
vations of remarkably slow progression of a-syn pathol-
ogy in PD patients (Halliday et al., 2008; Kim et al., 2014),
thus confirming the feasibility of the a-syn PFF infusion
paradigm as a tool for modeling aspects of cognitive loss
n PD. In fact, a significant trend toward a worsened per-
formance in the RAWM task was seen from ninemonths
postinjection, to become dramatically evident at 12months.
Interestingly, at no time point postinjection was any motor
disturbance detected in the injected animals, nor was
a-syn found within regions rich in dopamine neurons and fi-
bers, such as the SN, the VTA or the striatum. In addition,
no obvious loss in dopaminergic, noradrenergic, or cholin-
ergic immunoreactivity was detected in a-syn-injected
animals compared with controls, thus the behavioral im-
pairments seen in the a-syn-injected animals appear to be
determined by the long-term persisting a-syn neuropathol-
ogy in the affected neurons rather than by neurodegenera-
tion, which is consistent with the observations by Hall et al.
(2013). These observations are also in keeping with the find-
ings of a recent in vitro study (Froula et al., 2018) showing
that treatment of excitatory hippocampal neurons with
a-syn fibrils induced neuronal dysfunctions, such as a re-
duced frequency and amplitudes of spontaneous Ca21
transients (Overk et al., 2015), as well as a dramatic disrup-
tion of synaptic activity, and accelerated neuronal death
(Wu et al., 2019). In particular, the reduced spine density in-
duced by a-synucleinopathy may be a pathophysiological
phenotype contributing to dementia (Blumenstock et al.,
2017; Kramer and Schulz-Schaeffer, 2007). Froula and col-
leagues also found some compensatory mechanisms re-
sponding to synaptic defects induced by a-syn fibrils,
which could explain the long-time window before the onset
of memory impairments (Froula et al., 2018).
Considering the occurrence of a-syn immunoreactivity
in the entorhinal cortex and, at 12months postinjection, in
the vDBB and the piriform cortices, i.e., all regions in-
volved in memory functions and the time course and re-
gional pattern of a-syn accumulation, the present data
therefore suggest that hippocampal Lewy pathology must
spread beyond its initial site, toward cognitively-relevant
areas, to induce measurable memory dysfunctions. This
is consistent with the model proposed by Adamowicz et
al. (2017), according to which learning, and memory, im-
pairment become apparent once LB pathology concur-
rently affects CA1 and entorhinal cortex.
The mechanism underlying such spreading needs to be
further elucidated. However, it has been reported that def-
icits in learning and memory observed in a-syn transgenic
mice are accompanied by alterations in postsynaptic den-
sities (Masliah et al., 2011) or reduction in presynaptic
vesicle-associated proteins such as synaptophysin (Lim
et al., 2011), suggesting that the toxicity of a-syn may be
mediated by disturbances in synaptic transmission
(Larsen et al., 2006; Nemani et al., 2010). Here, we did not
find any colocalization of synapsin-1 immunoreactivity in
a-syn-positive hippocampal neurons (data not shown),
which nevertheless does not exclude such possibility and
warrants further analyses.
In a recent investigation, Aulic et al. (2017) found that the
PrPC binds a-syn amyloids to get access into the cell and
accumulate into cytoplasm, thereby facilitating the cell-to-
cell spreading of the pathology. Likewise, it has been re-
ported that a-syn oligomeric species interact with PrPC
through mGluR5, activating SFK kinases and, subse-
quently, NMDAR2B to induce neuronal dysfunction and
cognitive deficits in Thy1-aSyn mice and also that the toxic
effects induced by a-syn oligomers may be prevented
using antibody-mediated inactivation of PrPC (Ferreira et
al., 2017). Taken together, these studies have identified
previously unknown components of the signaling cascade
triggered by a-syn, therefore suggesting that PrPC signal-
ing might be involved in the pathogenesis of synucleinopa-
thies and may be used as a potential therapeutic target to
prevent or slow down the progression of synucleinopathies.
Considering that the a-syn-PrPC interactions reported by
both Aulic et al. (2017) and Ferreira et al. (2017) are de-
tected in five- to eight-month-old animals, it is possible to
assume the existence of specific stages during which the
interaction of these proteins may actually take place, lead-
ing to a massive a-syn spreading, to become less pro-
nounced at later time points, once the spreading has
occurred. This may be of potential interest, as it may
Figure 12. Quantification of the mRNA expression levels of Snca and Prnp in prefrontal cortex (A) and in the hippocampus (B) of
rats injected with a-syn fibrils and controls at 12months postinjection. Data are represented as mean fold change over control 6
SEM.
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highlight a valuable window of therapeutic opportunity,
whose full understanding, again, requires further
investigation.
PrPC levels in the hippocampus, prefrontal and fronto-
parietal cortices of a-syn-injected rats was similar to con-
trols at 12months postinjection, as well as Prnp mRNA
and Snca mRNA levels in the prefrontal cortex which is
consistent with previous observations (Aulic et al., 2017).
This finding appears to confirm that the level of PrPC and
a-syn transcripts were not altered after fibrils injection
and that the observed increase of pathologic a-syn is
likely to occur at protein level.
Increased level of phosphorylated a-syn at Ser129 rep-
resents one of the hallmarks of PD. In fact,;90% of a-syn
deposited in LBs is phosphorylated at Ser129 while only
4% or less of the total a-syn is phosphorylated at this resi-
due in brains from individuals without PD (Fujiwara et al.,
2002; Anderson et al., 2006). Nevertheless, the significance
of phosphorylation in the biology and pathophysiology of
the protein is still controversial, and both in vitro and in vivo
studies, examining phosphorylation of a-syn at different
sites, have reported conflicting results, showing either pro-
motion (Smith et al., 2005), inhibition (Paleologou et al.,
2008), or no effect (Fiske et al., 2011) on inclusion forma-
tion. However, to assess the role, if any, of the phosphoryl-
ation of a-syn fibrils in the seeding and pathologic
accumulation of a-syn, it was found that P-PFF are more
efficiently uptaken by neurons after injection in wild-type
mice, leading to increased seeding and accumulation of
the endogenous a-syn (Karampetsou et al., 2017). This evi-
dence suggests that phosphorylation may promote aggre-
gation to the a-syn assemblies and as such may regulate
the onset of neuronal dysfunction. Similarly, we found after
injection of non-phosphorylated recombinant mouse a-syn
fibrils in rats, a time-dependent increase of Ser129-phos-
phorylated a-syn into the hippocampus with the overt
manifestation of cognitive deficits. Our data, therefore, not
only provide a further proof of the importance of phospho-
rylation in the pathogenesis of disease but also allow the
validation of our experimental model.
In conclusion, our study shows that bilateral injection of
recombinant a-syn PFF into the hippocampus of rat is
sufficient to trigger a-syn pathology within the hippocam-
pus, which spreads to entorhinal cortex, vDBB, and piri-
form cortex, and leads to working memory impairment.
Although the mechanism behind a-syn-mediated working
memory impairment has to be further elucidated, the
present study provides an additional proof that a-syn may
be one the main neuronal substrates for cognitive impair-
ment in synucleinopathies.
References
Aarsland D, Perry R, Brown A, Larsen JP, Ballard C (2005)
Neuropathology of dementia in Parkinson’s disease: a prospec-
tive, community-based study. Ann Neurol 58:773–776.
Adamowicz DH, Roy S, Salmon DP, Galasko DR, Hansen LA,
Masliah E, Gage FH (2017) Hippocampal a-synuclein in dementia
with Lewy bodies contributes to memory impairment and is con-
sistent with spread of pathology. J Neurosci 37:1675–1684.
Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K,
Caccavello RJ, Barbour R, Huang J, Kling K, Lee M, Diep L, Keim
PS, Shen X, Chataway T, Schlossmacher MG, Seubert P, Schenk
D, Sinha S, Gai WP, et al. (2006) Phosphorylation of Ser-129 is the
dominant pathological modification of a-synuclein in familial and
sporadic Lewy body disease. J Biol Chem 281:29739–29752.
Antony PMA, Diederich NJ, Balling R (2011) Parkinson’s disease
mouse models in translational research. Mamm Genome 22:401–
419.
Apaydin H, Ahlskog JE, Parisi JE, Boeve BF, Dickson DW (2002)
Parkinson disease neuropathology: later-developing dementia
and loss of the levodopa response. Arch Neurol 59:102–112.
Aulic S, Le TT, Moda F, Abounit S, Corvaglia S, Casalis L, Gustincich
S, Zurzolo C, Tagliavini F, Legname G (2014) Defined a-synuclein
prion-like molecular assemblies spreading in cell culture. BMC
Neurosci 15:69.
Aulic S, Masperone L, Narkiewicz J, Isopi E, Bistaffa E, Ambrosetti E,
Pastore B, De Cecco E, Scaini D, Zago P, Moda F, Tagliavini F,
Legname G (2017) a-Synuclein amyloids hijack prion protein to
gain cell entry, facilitate cell-to-cell spreading and block prion rep-
lication. Sci Rep 7:10050.
Blesa J, Przedborski S (2014) Parkinson’s disease: animal models
and dopaminergic cell vulnerability. Front Neuroanat 8:155.
Blumenstock S, Rodrigues EF, Peters F, Blazquez-Llorca L, Schmidt
F, Giese A, Herms J (2017) Seeding and transgenic overexpression
of alpha-synuclein triggers dendritic spine pathology in the neo-
cortex. EMBOMol Med 9:716–731.
Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak
E (2003) Staging of brain pathology related to sporadic
Parkinson’s disease. Neurobiol Aging 24:197–211.
Bradley VA, Welch JL, Dick DJ (1989) Visuospatial working memory
in Parkinson’s disease. J Neurol Neurosurg Psychiatry 52:1228–
1235.
Breese GR, Traylor TD (1971) Depletion of brain noradrenaline and
dopamine by 6-hydroxydopamine. Br J Pharmacol 42:88–99.
Coradazzi M, Gulino R, Fieramosca F, Falzacappa LV, Riggi M,
Leanza G (2016) Selective noradrenaline depletion impairs working
memory and hippocampal neurogenesis. Neurobiol Aging 48:93–
102.
Dev KK, Hofele K, Barbieri S, Buchman VL, van der Putten H (2003)
Part II: a-synuclein and its molecular pathophysiological role in
neurodegenerative disease. Neuropharmacology 45:14–44.
Decressac M, Mattsson B, Lundblad M, Weikop P, Björklund A
(2012) Progressive neurodegenerative and behavioural changes
induced by AAV-mediated overexpression of a-synuclein in mid-
brain dopamine neurons. Neurobiol Dis 45:939–953.
Eliezer D, Kutluay E, Bussell R, Browne G (2001) Conformational
properties of a-synuclein in its free and lipid-associated states. J
Mol Biol 307:1061–1073.
Ferreira DG, Temido-Ferreira M, Vicente Miranda H, Batalha VL,
Coelho JE, Szegö ÉM, Marques-Morgado I, Vaz SH, Rhee JS,
Schmitz M, Zerr I, Lopes LV, Outeiro TF (2017) a-synuclein inter-
acts with PrPC to induce cognitive impairment through mGluR5
and NMDAR2B. Nat Neurosci 20:1569–1579.
Fiske M, Valtierra S, Solvang K, Zorniak M, White M, Herrera S,
Konnikova A, Brezinsky R, Debburman S (2011) Contribution of al-
anine-76 and serine phosphorylation in a-synuclein membrane as-
sociation and aggregation in yeasts. Parkinsons Dis 2011:392180.
Froula JM, Henderson BW, Gonzalez JC, Vaden JH, McLean JW,
Wu Y, Banumurthy G, Overstreet-Wadiche L, Herskowitz JH,
Volpicelli-Daley LA (2018) a-Synuclein fibril-induced paradoxical
structural and functional defects in hippocampal neurons. Acta
Neuropathol Commun 6:35.
Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E,
Goldberg MS, Shen J, Takio K, Iwatsubo T (2002) a-Synuclein is
phosphorylated in synucleinopathy lesions. Nat Cell Biol 4:160–
164.
Gulino R, Vicario N, Giunta MAS, Spoto G, Calabrese G, Vecchio M,
Gulisano M, Leanza G, Parenti R (2019) Neuromuscular plasticity
Research Article: New Research 18 of 20
May/June 2020, 7(3) ENEURO.0009-20.2020 eNeuro.org
in a mouse neurotoxic model of spinal motoneuronal loss. Int J
Mol Sci 20:1500.
Gundersen HJG, Jensen EB (1987) The efficiency of systematic sam-
pling in stereology and its prediction. J Microsc 147:229–263.
Hall H, Jewett M, Landeck N, Nilsson N, Schagerlöf U, Leanza G,
Kirik D (2013) Characterization of cognitive deficits in rats overex-
pressing human alpha-synuclein in the ventral tegmental area and
medial septum using recombinant adeno-associated viral vectors.
PLoS One 8:e64844.
Halliday G, Hely M, Reid W, Morris J (2008) The progression of pa-
thology in longitudinally followed patients with Parkinson’s dis-
ease. Acta Neuropathol 115:409–415.
Harding AJ, Halliday GM (2001) Cortical Lewy body pathology in the
diagnosis of dementia. Acta Neuropathol 102:355–363.
Huang C, Ren G, Zhou H, Wang C-c (2005) A new method for purifi-
cation of recombinant human alpha-synuclein in Escherichia coli.
Protein Expr Purif 42:173–177.
Hurtig HI, Trojanowski JQ, Galvin J, Ewbank D, Schmidt ML, Lee
VM, Clark CM, Glosser G, Stern MB, Gollomp SM, Arnold SE
(2000) Alpha-synuclein cortical Lewy bodies correlate with demen-
tia in Parkinson’s disease. Neurology 54:1916–1921.
Irwin DJ, White MT, Toledo JB, Xie SX, Robinson JL, Van Deerlin V,
Lee VM-Y, Leverenz JB, Montine TJ, Duda JE, Hurtig HI,
Trojanowski JQ (2012) Neuropathologic substrates of Parkinson’s
disease dementia. Ann Neurol 72:587–598.
Jackson-Lewis V, Blesa J, Przedborski S (2012) Animal models of
Parkinson’s disease. Parkinsonism Relat Disord 18:S183–S185.
Karampetsou M, Ardah MT, Semitekolou M, Polissidis A, Samiotaki
M, Kalomoiri M, Majbour N, Xanthou G, El-Agnaf OMA, Vekrellis
K (2017) Phosphorylated exogenous alpha-synuclein fibrils exac-
erbate pathology and induce neuronal dysfunction in mice. Sci
Rep 7:16533.
Kim WS, Kågedal K, Halliday GM (2014) Alpha-synuclein biology in
Lewy body diseases. Alzheimers Res Ther 6:73.
Kirik D, Rosenblad C, Burger C, Lundberg C, Johansen TE,
Muzyczka N, Mandel RJ, Björklund A (2002) Parkinson-like neuro-
degeneration induced by targeted overexpression of alpha-synu-
clein in the nigrostriatal system. J Neurosci 22:2780–2791.
Kövari E, Gold G, Herrmann FR, Canuto A, Hof PR, Bouras C,
Giannakopoulos P (2003) Lewy body densities in the entorhinal
and anterior cingulate cortex predict cognitive deficits in
Parkinson’s disease. Acta Neuropathol 106:83–88.
Kramer ML, Schulz-Schaeffer WJ (2007) Presynaptic a-synuclein ag-
gregates, not Lewy bodies, cause neurodegeneration in dementia
with Lewy bodies. J Neurosci 27:1405–1410.
Langston JW, Langston EB, Irwin I (1984) MPTP-induced parkinson-
ism in human and non-human primates–clinical and experimental
aspects. Acta Neurol Scand Suppl 100:49–54.
Larsen KE, Schmitz Y, Troyer MD, Mosharov E, Dietrich P, Quazi AZ,
Savalle M, Nemani V, Chaudhry FA, Edwards RH, Stefanis L,
Sulzer D (2006) a-Synuclein overexpression in PC12 and chromaf-
fin cells impairs catecholamine release by interfering with a late
step in exocytosis. J Neurosci 26:11915–11922.
Lee SJ, Desplats P, Sigurdson C, Tsigelny I, Masliah E (2010)
Pathological propagation through cell-to-cell transmission of non-
prion protein aggregates in neurodegenerative disorders. Nat Rev
Neurol 6:702–706.
Lim Y, Kehm VM, Lee EB, Soper JH, Li C, Trojanowski JQ, Lee VMY
(2011) a-Syn suppression reverses synaptic and memory defects
in a mouse model of dementia with Lewy bodies. J Neurosci
31:10076–10087.
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression
data using real-time quantitative PCR and the 2(-Delta Delta C(T))
method. Methods 25:402–408.
Luk KC, Song C, O’Brien P, Stieber A, Branch JR, Brunden KR,
Trojanowski JQ, Lee VM-Y (2009) Exogenous a-synuclein fibrils
seed the formation of Lewy body-like intracellular inclusions in cul-
tured cells. Proc Natl Acad Sci USA 106:20051–20056.
Luk KC, Kehm V, Carroll J, Zhang B, O’Brien P, Trojanowski JQ, Lee
VM-Y (2012) Pathological a-synuclein transmission initiates
Parkinson-like neurodegeneration in non-transgenic mice. Science
338:949–953.
Maroteaux L, Campanelli JT, Scheller RH (1988) Synuclein: a neu-
ron-specific protein localized to the nucleus and presynaptic nerve
terminal. J Neurosci 8:2804–2815.
Masliah E, Rockenstein E, Mante M, Crews L, Spencer B, Adame A,
Patrick C, Trejo M, Ubhi K, Rohn TT, Mueller-Steiner S, Seubert P,
Barbour R, McConlogue L, Buttini M, Games D, Schenk D (2011)
Passive immunization reduces behavioral and neuropathological
deficits in an alpha-synuclein transgenic model of Lewy body dis-
ease. PLoS One 6:e19338.
Masuda-Suzukake M, Nonaka T, Hosokawa M, Oikawa T, Arai T,
Akiyama H, Mann DMA, Hasegawa M (2013) Prion-like spreading
of pathological a-synuclein in brain. Brain 136:1128–1138.
McCann H, Stevens CH, Cartwright H, Halliday GM (2014)
a-Synucleinopathy phenotypes. Parkinsonism Relat Disord 20:
S62–S67.
Meredith GE, Sonsalla PK, Chesselet MF (2008) Animal models of
Parkinson’s disease progression. Acta Neuropathol 115:385–398.
Morris R (1984) Developments of a water-maze procedure for study-
ing spatial learning in the rat. J Neurosci Methods 11:47–60.
Nemani VM, Lu W, Berge V, Nakamura K, Onoa B, Lee MK,
Chaudhry FA, Nicoll RA, Edwards RH (2010) Increased expression
of alpha-synuclein reduces neurotransmitter release by inhibiting
synaptic vesicle reclustering after endocytosis. Neuron 65:66–79.
Oliveras-Salvá M, Van der Perren A, Casadei N, Stroobants S, Nuber
S, D’Hooge R, Van den Haute C, Baekelandt V (2013) rAAV2/7 vec-
tor-mediated overexpression of alpha-synuclein in mouse sub-
stantia nigra induces protein aggregation and progressive dose-
dependent neurodegeneration. Mol Neurodegener 8:44.
Overk CR, Rockenstein E, Florio J, Cheng Q, Masliah E (2015)
Differential calcium alterations in animal models of neurodegener-
ative disease: reversal by FK506. Neuroscience 310:549–560.
Paleologou KE, Schmid AW, Rospigliosi CC, Kim HY, Lamberto GR,
Fredenburg RA, Lansbury PT Jr, Fernandez CO, Eliezer D,
Zweckstetter M, Lashuel HA (2008) Phosphorylation at Ser-129
but not the phosphomimics S129E/D inhibits the fibrillation of
alpha-synuclein. J Biol Chem 283:16895–16905.
Patterson JR, Duffy MF, Kemp CJ, Howe JW, Collier TJ, Stoll AC,
Miller KM, Patel P, Levine N, Moore DJ, Luk KC, Fleming SM,
Kanaan NM, Paumier KL, El-Agnaf OMA, Sortwell CE (2019) Time
course and magnitude of alpha-synuclein inclusion formation and
nigrostriatal degeneration in the rat model of synucleinopathy trig-
gered by intrastriatal alpha-synuclein preformed fibrils. Neurobiol
Dis 130:104525.
Paumier KL, Luk KC, Manfredsson FP, Kanaan NM, Lipton JW,
Collier TJ, Steece-Collier K, Kemp CJ, Celano S, Schulz E,
Sandoval IM, Fleming S, Dirr E, Polinski NK, Trojanowski JQ, Lee
VM, Sortwell CE (2015) Intrastriatal injection of pre-formed mouse
a-synuclein fibrils into rats triggers a-synuclein pathology and bi-
lateral nigrostriatal degeneration. Neurobiol Dis 82:185–199.
Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates.
Academic Press: San Diego.
Pintus R, Riggi M, Cannarozzo C, Valeri A, de Leo G, Romano M,
Gulino R, Leanza G (2018) Essential role of hippocampal noradren-
aline in the regulation of spatial working memory and TDP-43 tis-
sue pathology. J Comp Neurol 526:1131–1147.
Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra
A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES,
Chandrasekharappa S, Athanassiadou A, Papapetropoulos T,
Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI,
Nussbaum RL (1997) Mutation in the -synuclein gene identified in
families with Parkinson’s disease. Science 276:2045–2047.
Sasaki A, Arawaka S, Sato H, Kato T (2015) Sensitive western blot-
ting for detection of endogenous Ser129-phosphorylated a-synu-
clein in intracellular and extracellular spaces. Sci Rep 5:14211.
Schober A (2004) Classic toxin-induced animal models of
Parkinson’s disease: 6-OHDA and MPTP. Cell Tissue Res
318:215–224.
Research Article: New Research 19 of 20
May/June 2020, 7(3) ENEURO.0009-20.2020 eNeuro.org
Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus
J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S,
Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR,
Muenter M, Baptista M, Miller D, Blancato J, et al. (2003)
a-Synuclein locus triplication causes Parkinson’s disease.
Science 302:841–841.
Smith WW, Margolis RL, Li X, Troncoso JC, Lee MK, Dawson VL,
Dawson TM, Iwatsubo T, Ross CA (2005) a-Synuclein phosphoryl-
ation enhances eosinophilic cytoplasmic inclusion formation in
SH-SY5Y cells. J Neurosci 25:5544–5552.
Squire LR (1992) Declarative and nondeclarative memory: multiple
brain systems supporting learning and memory. J Cogn Neurosci
4:232–243.
Uversky VN (2007) Neuropathology, biochemistry, and biophysics of
a-synuclein aggregation. J Neurochem 103:17–37.
Vanni S, Pecci R, Edlow JA, Nazerian P, Santimone R, Pepe G,
Moretti M, Pavellini A, Caviglioli C, Casula C, Bigiarini S,
Vannucchi P, Grifoni S (2017) Differential diagnosis of vertigo
in the emergency department: a prospective validation study
of the STANDING algorithm. Front Neurol 8:590.
Visanji NP, Brotchie JM, Kalia LV, Koprich JB, Tandon A, Watts JC,
Lang AE (2016) a-Synuclein-based animal models of Parkinson’s
disease: challenges and opportunities in a new era. Trends
Neurosci 39:750–762.
Volpicelli-Daley LA, Luk KC, Patel TP, Tanik SA, Riddle DM, Stieber
A, Meaney DF, Trojanowski JQ, Lee VM (2011) Exogenous a-synu-
clein fibrils induce Lewy body pathology leading to synaptic dys-
function and neuron death. Neuron 72:57–71.
West MJ, Slomianka L, Gundersen HJG (1991) Unbiased stereologi-
cal estimation of the total number of neurons in the subdivisions of
the rat hippocampus using the optical fractionator. Anat Rec
231:482–497.
Wu Q, Takano H, Riddle DM, Trojanowski JQ, Coulter DA, Lee VM
(2019) a-Synuclein (aSyn) preformed fibrils induce endogenous
aSyn aggregation, compromise synaptic activity and enhance
synapse loss in cultured excitatory hippocampal neurons. J
Neurosci 39:5080–5094.
Research Article: New Research 20 of 20
May/June 2020, 7(3) ENEURO.0009-20.2020 eNeuro.org
